CD274 and cervical carcinoma: For example, the phase II NACI‐CERV‐001 showed an ORR of 98% when using cisplatin, nab‐paclitaxel, and camrelizumab before radical surgery or CCRT in patients with Stage I B3, IIA2, larger than 4 cm IIB/IIIC1r, PD‐L1 positive cervical cancer.55